Financial Assistance
Newsletter Sign-up
Need Appointment
Contact Us
About Us

Rush University
For Physicians
For Rush Employees
For Students
Bill Payment Center
Rotate
<< Previous | New Search | Return to Search Results | Next >>

Lydia Usha, MD

Lydia Usha, MD
Appointment Request

Or call
(888) 352-RUSH for help arranging an appointment.
Specialty:
  • Oncology, Medical
  • Internal Medicine
Board Certification:
  • Medical Oncology
Faculty Rank: Associate Professor
Medical or Graduate Education: St. Petersburg Institute of Public Health, Russia
Residency: California Pacific Medical Center - Internal Medicine
Fellowship: University of Illinois Medical Center - Hematology/Oncology
Clinical Expertise:
  • Breast cancer
  • Cancer risk assessment and counseling
  • Cervical cancer
  • Endometrial cancer
  • Genetic testing
  • Gynecologic cancer
  • Ovarian cancer
  • Uterine cancer
Research Interests:
  • Treatments for breast cancer
  • Treatments for gynecologic cancer
  • Screening, risk assessment, and management of hereditary predisposition to cancer
  • Clinical trials for gynecologic cancer
Languages Spoken:
  • Russian
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

  1. Mesenchymal stem cells develop tumor tropism but do not accelerate breast cancer tumorigenesis in a somatic mouse breast cancer model.
    Usha L, Rao G, Christopherson Ii K, Xu X
    PLoS ONE
    2013
    8(9):e67895.
    eng
  2. Hereditary inflammatory breast cancer associated with BRCA2 mutation: a rare disease presentation in mother and daughter.
    Jimenez AM, Growney A, Behrens G, Corbridge C, Chapman DD, Usha L.
    Clin Adv Hematol Oncol. 2012
    2012 Jun
    10(6):402-4. No abstract available.
  3. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
    Kunos C, Radivoyevitch T, Abdul-Karim FW, Fanning J, Abulafia O, Bonebrake AJ, Usha L.
    J Transl Med. 2012
    2012 Apr 27
    10:79. doi: 10.1186/1479-5876-10-79.
  4. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
    Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.
    Gynecol Oncol. 2011
    2011 Jun 1
    121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.
  5. Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.
    Usha L, Tabesh B, Morrison LE, Rao RD, Jacobson K, Zhu A, Basu S, Coon JS.
    J Hematol Oncol. 2008
    2008 Aug 14
    1:12. doi: 10.1186/1756-8722-1-12.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript

Find a Doctor | Patient & Visitor Services | Health Information | Clinical Services | Events & Classes | News Room | Clinical Trials | Research at Rush
Nursing at Rush | Work at Rush | Giving to Rush | Directions to Rush | Disclaimer | Privacy Statement
For Physicians | For Rush Employees | For Students | Bill Payment Center | Site Map
© Rush University Medical Center
1653 W. Congress Parkway, Chicago, Illinois 60612